作者
Augusto Di Castelnuovo, Simona Costanzo, Andrea Antinori, Nausicaa Berselli, Lorenzo Blandi, Raffaele Bruno, Roberto Cauda, Giovanni Guaraldi, Lorenzo Menicanti, Ilaria My, Giustino Parruti, Giuseppe Patti, Stefano Perlini, Francesca Santilli, Carlo Signorelli, Enrico Spinoni, Giulio G Stefanini, Alessandra Vergori, Walter Ageno, Antonella Agodi, Luca Aiello, Piergiuseppe Agostoni, Samir Al Moghazi, Marinella Astuto, Filippo Aucella, Greta Barbieri, Alessandro Bartoloni, Marialaura Bonaccio, Paolo Bonfanti, Francesco Cacciatore, Lucia Caiano, Francesco Cannata, Laura Carrozzi, Antonio Cascio, Arturo Ciccullo, Antonella Cingolani, Francesco Cipollone, Claudia Colomba, Francesca Crosta, Chiara Dal Pra, Gian Battista Danzi, Damiano D'Ardes, Katleen de Gaetano Donati, Paola Del Giacomo, Francesco Di Gennaro, Giuseppe Di Tano, Giampiero D'Offizi, Tommaso Filippini, Francesco Maria Fusco, Ivan Gentile, Alessandro Gialluisi, Giancarlo Gini, Elvira Grandone, Leonardo Grisafi, Gabriella Guarnieri, Silvia Lamonica, Francesco Landi, Armando Leone, Gloria Maccagni, Sandro Maccarella, Andrea Madaro, Massimo Mapelli, Riccardo Maragna, Lorenzo Marra, Giulio Maresca, Claudia Marotta, Franco Mastroianni, Maria Mazzitelli, Alessandro Mengozzi, Francesco Menichetti, Marianna Meschiari, Filippo Minutolo, Arturo Montineri, Roberta Mussinelli, Cristina Mussini, Maria Musso, Anna Odone, Marco Olivieri, Emanuela Pasi, Francesco Petri, Biagio Pinchera, Carlo A Pivato, Venerino Poletti, Claudia Ravaglia, Massimo Rinaldi, Andrea Rognoni, Marco Rossato, Ilaria Rossi, Marianna Rossi, Anna Sabena, Francesco Salinaro, Vincenzo Sangiovanni, Carlo Sanrocco, Laura Scorzolini, Raffaella Sgariglia, Paola Giustina Simeone, Michele Spinicci, Enrico Maria Trecarichi, Amedeo Venezia, Giovanni Veronesi, Roberto Vettor, Andrea Vianello, Marco Vinceti, Laura Vocciante, Raffaele De Caterina, Licia Iacoviello
发表日期
2020/12/1
期刊
European Journal of Internal Medicine
卷号
82
页码范围
38-47
出版商
Elsevier
简介
Background
Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19.
Objective
We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality.
Methods
In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses.
Results
Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7 …
学术搜索中的文章
A Di Castelnuovo, S Costanzo, A Antinori, N Berselli… - European Journal of Internal Medicine, 2020